
Screened
N=244
81 subjects not eligible
•Did not meet inclusion/exclusion criteria
Entered run-in
N=163
Randomised
N=163
Modified Intent-to-Treat population
Placebo
N=60
UMEC
QD
BID
15.6 µg
N=60
31.25 µg
N=57
62.5 µg
N=59
125 µg
N=60
15.6 µg
N=56
31.25 µg
N=58
Tiotropium QD
18 µg
N=56
Completed treatment period
Placebo
N=59
UMEC
QD
BID
15.6 µg
N=58
31.25 µg
N=56
62.5 µg
N=59
125 µg
N=58
15.6 µg
N=55
31.25 µg
N=56
Tiotropium QD
18 µg
N=56
Withdrawn during treatment period
Placebo
N=1
UMEC
QD
BID
15.6 µg
N=2
31.25 µg
N=1
62.5 µg
N=0
125 µg
N=2
15.6 µg
N=1
31.25 µg
N=2
Tiotropium QD
18 µg
N=0
Withdrawals
9 subjects withdrew during treatment
•Lack of efficacy (n=3)
•Adverse events (n=3)*
•Lost to follow-up (n=1)
•Protocol deviation (n=1)
•Withdrew consent (n=1)
Withdrawn during washout period
Placebo
N=1
UMEC
QD
BID
15.6 µg
N=0
31.25 µg
N=0
62.5 µg
N=0
125 µg
N=2
15.6 µg
N=0
31.25 µg
N=1
Tiotropium QD
18 µg
N=3
Withdrawals
7 subjects withdrew during washout
•Lack of efficacy (n=1)
•Adverse events (n=1)†
•Withdrew consent (n=5)
Completed all treatment periods
N=147